Precision Bio Gets FDA Rare Disease Nod for DMD Therapy
June 25, 2025
Precision BioSciences, a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet need,
